TEVA, US8816242098

Barclays keeps Buy rating for Teva stock at USD 42.00

Published on 10/14/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 4.14 billion. Teva stock last stood at USD 41.25 on October 13, 2026, up 0.19 percent versus its USD 41.17 prior close.

Analyst target and reporting date

Barclays maintained a Buy rating and set a USD 42.00 target on October 12, 2026.
Second-quarter 2026 revenue was USD 4.14 billion, while GAAP net loss reached USD 576.00 million.
Teva stock last stood at USD 41.25 on October 13, 2026 at 4:00 p.m. ET, up 0.19 percent versus its USD 41.17 prior close.
Teva is scheduled to report its third-quarter results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries (US8816242098) was last quoted at USD 41.25 on October 13, 2026 at 4:00 p.m. ET, up 0.19 percent versus its USD 41.17 prior close. Barclays maintained a Buy rating and set a USD 42.00 price target on October 12, 2026, placing the target 1.82 percent above the quoted price, according to Markets Insider.

Quarterly revenue and loss

Teva reported USD 4.14 billion of revenue in the second quarter of 2026, down 0.91 percent from USD 4.18 billion a year earlier, according to Markets Insider. GAAP net loss was USD 576.00 million, compared with a USD 282.00 million profit in the year-earlier quarter. The revenue comparison points to a weaker top line even as the company approaches its next reporting date.

Stock stays near yearly high

The USD 41.25 price stood USD 0.77 below Teva's 52-week high of USD 42.02 and USD 22.42 above its 52-week low of USD 18.83. That places the stock 1.83 percent below its high and 119.17 percent above its low.

Trading volume reached 6,818,475 shares on October 13, 2026, compared with an average volume of 5,512,568 shares. The price therefore remained close to the upper end of its annual range while the latest completed session showed only a 0.19 percent gain.

Valuation and reporting date

Teva had a market capitalization of USD 48.0 billion and a trailing P/E ratio of 68.66 as of October 13, 2026. The company is scheduled to report third-quarter results on November 3, 2026, according to Yahoo Finance.

For investors, the upcoming report will put the USD 4.14 billion second-quarter revenue base and the USD 576.00 million GAAP loss into a new time frame. The analyst target of USD 42.00 sits close to the current annual high, leaving the next results as the next dated company checkpoint.

October 13 price remains elevated

Teva's latest quoted price was USD 41.25 on October 13, 2026 at 4:00 p.m. ET, up 0.19 percent versus the USD 41.17 prior close. The USD 42.02 high and USD 18.83 low define the current 52-week frame.